The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes
Authors:
Open Access
- 30 March 2016
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 280 (1) , 24-38
Abstract
The aim of this review was to summarize recent advances in the understanding of the clinical and autoantibody phenotypes, their associated outcomes and the pathogenesis of the juvenile idiopathic inflammatory myopathies (JIIMs). The major clinical and autoantibody phenotypes in children have many features similar to those in adults, and each has distinct demographic and clinical features and associated outcomes. The most common myositis autoantibodies in JIIM patients are anti‐p155/140, anti‐MJ and anti‐MDA5. Higher mortality has been associated with overlap myositis as well as with the presence of anti‐synthetase and anti‐MDA5 autoantibodies; a chronic illness course and lipodystrophy have been associated with anti‐p155/140 autoantibodies; and calcinosis has been associated with anti‐MJ autoantibodies. Histologic abnormalities of JIIMs detectable on muscle biopsy have also been correlated with myositis‐specific autoantibodies; for example, patients with anti‐MDA5 show low levels of inflammatory infiltrate and muscle damage on biopsy. The first genome‐wide association study of adult and juvenile dermatomyositis revealed three novel genetic associations, BLK, PLCL1 and CCL21 and confirmed that the human leucocyte antigen region is the primary risk region for juvenile dermatomyositis. Here, we review the well‐established pathogenic processes in JIIMs, including the type 1 interferon and endoplasmic reticulum stress pathways. Several novel JIIM‐associated inflammatory mediators, such as the innate immune system proteins, myeloid‐related peptide 8/14, galectin 9 and eotaxin, have emerged as promising biomarkers of disease. Advances in our understanding of the phenotypes and pathophysiology of the JIIMs are leading to better tools to help clinicians stratify and treat these heterogeneous disorders.Keywords
Funding Information
- National Institutes of Health
- National Institute of Environmental Health Sciences
- JM Foundation
This publication has 96 references indexed in Scilit:
- Most Patients With Cancer‐Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP‐2 or Transcription Intermediary Factor 1γArthritis & Rheumatism, 2013
- Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weaknessSkeletal Muscle, 2013
- Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneityArthritis & Rheumatism, 2011
- The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective studyJournal of the American Academy of Dermatology, 2011
- Type I interferon: friend or foe?Journal of Experimental Medicine, 2010
- Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatmentBest Practice & Research Clinical Rheumatology, 2009
- Autoantibodies to a 140‐kd protein in juvenile dermatomyositis are associated with calcinosisArthritis & Rheumatism, 2009
- Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositisArthritis & Rheumatism, 2008
- Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of SeverityMedicine, 2008
- Persistent association of nailfold capillaroscopy changes and skin involvement over thirty‐six months with duration of untreated disease in patients with juvenile dermatomyositisArthritis & Rheumatism, 2008